{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:19:17Z","timestamp":1792783157426,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shire International GmbH, a Takeda company, Zurich, Switzerland"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A systematic literature review was performed to summarize the frequency and nature of renal complications in patients with chronic hypoparathyroidism managed with conventional therapy. Methodology was consistent with the recommendations outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Peer-reviewed journal articles with specified medical subject heading terms were identified using the PubMed, EMBASE, and Cochrane databases. Data were extracted from eligible articles based on prespecified parameters for clinical outcomes of renal calcifications and disease. Because of the heterogeneity of the data, a meta-analysis could not be conducted. From 1200 potentially relevant articles, data were extracted from 13 manuscripts that reported data for \u22651 of the 19 predefined renal outcomes for \u226510 adult patients (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200911 manuscripts) or pediatric patients (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20092 manuscripts). The collective data provide evidence that adult and pediatric patients with chronic hypoparathyroidism and treated with conventional therapy (oral calcium and active vitamin D) had an increased risk of renal complications. The reported rate of nephrolithiasis was up to 36%, with the lowest rates in studies reporting shorter duration of disease. The rate of nephrocalcinosis was up to 38%. Some studies reported a combined nephrolithiasis\/nephrocalcinosis outcome of 19% to 31%. Data for renal disease that encompassed a range of renal insufficiency to chronic kidney disease were reported in 10 articles; the reported rates ranged from 2.5% to 41%. In patients who receive long-term treatment with oral calcium and active vitamin D, chronic hypoparathyroidism may be associated with an increased risk of renal complications compared with the general population.\n                  <\/jats:p>","DOI":"10.1007\/s11154-020-09613-1","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T10:07:09Z","timestamp":1613729229000},"page":"297-316","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8392-8004","authenticated-orcid":false,"given":"Elvira O.","family":"Gosmanova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4953-6917","authenticated-orcid":false,"given":"Pascal","family":"Houillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2152-4247","authenticated-orcid":false,"given":"Lars","family":"Rejnmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5783-1142","authenticated-orcid":false,"given":"Claudio","family":"Marelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1570-2617","authenticated-orcid":false,"given":"John P.","family":"Bilezikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"issue":"4","key":"9613_CR1","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.ecl.2018.07.012","volume":"47","author":"M Babey","year":"2018","unstructured":"Babey M, Brandi ML, Shoback D. Conventional treatment of hypoparathyroidism. Endocrinol Metab Clin N Am. 2018;47(4):889\u2013900.","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"4","key":"9613_CR2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1056\/NEJMcp0803050","volume":"359","author":"D Shoback","year":"2008","unstructured":"Shoback D. Hypoparathyroidism. N Engl J Med. 2008;359(4):391\u2013403.","journal-title":"N Engl J Med"},{"issue":"12","key":"9613_CR3","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1359\/jbmr.080803","volume":"23","author":"MR Rubin","year":"2008","unstructured":"Rubin MR, Dempster DW, Zhou H, Shane E, Nickolas T, Sliney J Jr, et al. Dynamic and structural properties of the skeleton in hypoparathyroidism. J Bone Miner Res. 2008;23(12):2018\u201324.","journal-title":"J Bone Miner Res"},{"key":"9613_CR4","doi-asserted-by":"crossref","unstructured":"Shoback DM, Bilezikian JP, Costa AG, Dempster D, Dralle H, Khan AA, et al. Presentation of hypoparathyroidism: etiologies and clinical features. J Clin Endocrinol Metab. 2016;101(6):2300\u201312.","DOI":"10.1210\/jc.2015-3909"},{"key":"9613_CR5","doi-asserted-by":"crossref","unstructured":"Bilezikian JP, Brandi ML, Cusano NE, Mannstadt M, Rejnmark L, Rizzoli R, et al. Management of hypoparathyroidism: present and future. J Clin Endocrinol Metab. 2016;101(6):2313\u201324.","DOI":"10.1210\/jc.2015-3910"},{"issue":"11","key":"9613_CR6","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1002\/jbmr.1979","volume":"28","author":"L Underbjerg","year":"2013","unstructured":"Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res. 2013;28(11):2277\u201385.","journal-title":"J Bone Miner Res"},{"issue":"9","key":"9613_CR7","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/jbmr.2501","volume":"30","author":"L Underbjerg","year":"2015","unstructured":"Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study. J Bone Miner Res. 2015;30(9):1738\u201344.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"9613_CR8","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/jbmr.3368","volume":"33","author":"L Underbjerg","year":"2018","unstructured":"Underbjerg L, Sikjaer T, Rejnmark L. Long-term complications in patients with hypoparathyroidism evaluated by biochemical findings: a case-control study. J Bone Miner Res. 2018;33(5):822\u201331.","journal-title":"J Bone Miner Res"},{"key":"9613_CR9","doi-asserted-by":"crossref","unstructured":"Mitchell DM, Regan S, Cooley MR, Lauter KB, Vrla MC, Becker CB, et al. Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab. 2012;97(12):4507\u201314.","DOI":"10.1210\/jc.2012-1808"},{"issue":"11","key":"9613_CR10","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1210\/jc.2015-2257","volume":"100","author":"I Levy","year":"2015","unstructured":"Levy I, Licht C, Daneman A, Sochett E, Harrington J. The impact of hypoparathyroidism treatment on the kidney in children: long-term retrospective follow-up study. J Clin Endocrinol Metab. 2015;100(11):4106\u201313.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"9613_CR11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264\u20139, W64.","journal-title":"Ann Intern Med"},{"key":"9613_CR12","doi-asserted-by":"crossref","unstructured":"Boyce AM, Shawker TH, Hill SC, Choyke PL, Hill MC, James R, et al. Ultrasound is superior to computed tomography for assessment of medullary nephrocalcinosis in hypoparathyroidism. J Clin Endocrinol Metab. 2013;98(3):989\u201394.","DOI":"10.1210\/jc.2012-2747"},{"issue":"5","key":"9613_CR13","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s00467-009-1116-y","volume":"25","author":"AP Evan","year":"2010","unstructured":"Evan AP. Physiopathology and etiology of stone formation in the kidney and the urinary tract. Pediatr Nephrol. 2010;25(5):831\u201341.","journal-title":"Pediatr Nephrol"},{"key":"9613_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fped.2018.00098","volume":"6","author":"A Weigert","year":"2018","unstructured":"Weigert A, Hoppe B. Nephrolithiasis and nephrocalcinosis in childhood-risk factor-related current and future treatment options. Front Pediatr. 2018;6:98.","journal-title":"Front Pediatr"},{"issue":"1","key":"9613_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/ki.2015.76","volume":"88","author":"L Shavit","year":"2015","unstructured":"Shavit L, Jaeger P, Unwin RJ. What is nephrocalcinosis? Kidney Int. 2015;88(1):35\u201343.","journal-title":"Kidney Int"},{"key":"9613_CR16","doi-asserted-by":"crossref","unstructured":"Dickson FJ, Sayer JA. Nephrocalcinosis: a review of monogenic causes and insights they provide into this heterogeneous condition. Int J Mol Sci. 2020;21(1):369.","DOI":"10.3390\/ijms21010369"},{"key":"9613_CR17","doi-asserted-by":"publisher","unstructured":"Priante G, Ceol M, Terrin L, Gianesello L, Quaggio F, Del Prete D, et al. Understanding the pathophysiology of nephrocalcinosis. Updates and advances in nephrolithiasis - pathophysiology, genetics, and treatment modalities. IntechOpen; 2017. https:\/\/doi.org\/10.5772\/intechopen.69895","DOI":"10.5772\/intechopen.69895"},{"key":"9613_CR18","doi-asserted-by":"crossref","unstructured":"Smith-Bindman R, Aubin C, Bailitz J, Bengiamin RN, Camargo CA Jr, Corbo J, et al. Ultrasonography versus computed tomography for suspected nephrolithiasis. N Engl J Med. 2014;371(12):1100\u201310.","DOI":"10.1056\/NEJMoa1404446"},{"issue":"7","key":"9613_CR19","doi-asserted-by":"publisher","first-page":"671","DOI":"10.4158\/EP13328.OR","volume":"20","author":"N Hadker","year":"2014","unstructured":"Hadker N, Egan J, Sanders J, Lagast H, Clarke BL. Understanding the burden of illness associated with hypoparathyroidism reported among patients in the PARADOX study. Endocr Pract. 2014;20(7):671\u20139.","journal-title":"Endocr Pract"},{"key":"9613_CR20","doi-asserted-by":"crossref","unstructured":"Arlt W, Fremerey C, Callies F, Reincke M, Schneider P, Timmermann W, et al. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol. 2002;146(2):215\u201322.","DOI":"10.1530\/eje.0.1460215"},{"issue":"10","key":"9613_CR21","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40618-018-0857-5","volume":"41","author":"A Meola","year":"2018","unstructured":"Meola A, Vignali E, Matrone A, Cetani F, Marcocci C. Efficacy and safety of long-term management of patients with chronic post-surgical hypoparathyroidism. J Endocrinol Investig. 2018;41(10):1221\u20136.","journal-title":"J Endocrinol Investig"},{"key":"9613_CR22","doi-asserted-by":"crossref","unstructured":"Bollerslev J, Rejnmark L, Marcocci C, Shoback DM, Sitges-Serra A, van Biesen W, et al. European Society of Endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol. 2015;173(2):G1\u2013G120.","DOI":"10.1530\/EJE-15-0628"},{"key":"9613_CR23","doi-asserted-by":"publisher","unstructured":"Bohrer T, Paul J, Krannich H, Hasse C, Elert O. The Wuerzburg scale: a new classification system for permanent postoperative hypoparathyroidism. Eur Surg. 2007(39\/1):39\u201344. https:\/\/doi.org\/10.1007\/s10353-006-0306-0","DOI":"10.1007\/s10353-006-0306-0"},{"key":"9613_CR24","doi-asserted-by":"crossref","unstructured":"Kim JH, Shin YL, Yang S, Cheon CK, Cho JH, Lee BH, et al. Diverse genetic aetiologies and clinical outcomes of paediatric hypoparathyroidism. Clin Endocrinol (Oxf). 2015;83(6):790\u20136.","DOI":"10.1111\/cen.12944"},{"key":"9613_CR25","doi-asserted-by":"crossref","unstructured":"Lopes MP, Kliemann BS, Bini IB, Kulchetscki R, Borsani V, Savi L, et al. Hypoparathyroidism and pseudohypoparathyroidism: etiology, laboratory features and complications. Arch Endocrinol Metab. 2016;60(6):532\u20136.","DOI":"10.1590\/2359-3997000000221"},{"issue":"12","key":"9613_CR26","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1055\/s-0042-118181","volume":"48","author":"G Leidig-Bruckner","year":"2016","unstructured":"Leidig-Bruckner G, Bruckner T, Raue F, Frank-Raue K. Long-term follow-up and treatment of postoperative permanent hypoparathyroidism in patients with medullary thyroid carcinoma: differences in complete and partial disease. Horm Metab Res. 2016;48(12):806\u201313.","journal-title":"Horm Metab Res"},{"issue":"8","key":"9613_CR27","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1210\/jc.2016-1477","volume":"101","author":"MC Astor","year":"2016","unstructured":"Astor MC, Lovas K, Debowska A, Eriksen EF, Evang JA, Fossum C, et al. Epidemiology and health-related quality of life in hypoparathyroidism in Norway. J Clin Endocrinol Metab. 2016;101(8):3045\u201353.","journal-title":"J Clin Endocrinol Metab"},{"key":"9613_CR28","doi-asserted-by":"crossref","unstructured":"Kidney Disease. Improving Global Outcomes. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2011;2017;7(1):1\u201359.","DOI":"10.1016\/j.kisu.2017.04.001"},{"issue":"2\u20133","key":"9613_CR29","first-page":"e86","volume":"12","author":"V Romero","year":"2010","unstructured":"Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol. 2010;12(2\u20133):e86\u201396.","journal-title":"Rev Urol"},{"issue":"1","key":"9613_CR30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1148\/radiol.2221010453","volume":"222","author":"KA Fowler","year":"2002","unstructured":"Fowler KA, Locken JA, Duchesne JH, Williamson MR. US for detecting renal calculi with nonenhanced CT as a reference standard. Radiology. 2002;222(1):109\u201313.","journal-title":"Radiology."},{"key":"9613_CR31","doi-asserted-by":"crossref","unstructured":"Xie Y, Bowe B, Mokdad AH, Xian H, Yan Y, Li T, et al. Analysis of the global burden of disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int. 2018;94(3):567\u201381.","DOI":"10.1016\/j.kint.2018.04.011"},{"key":"9613_CR32","doi-asserted-by":"crossref","unstructured":"Moon H, Chin HJ, Na KY, Joo KW, Kim YS, Kim S, et al. Hyperphosphatemia and risks of acute kidney injury, end-stage renal disease, and mortality in hospitalized patients. BMC Nephrol. 2019;20(1):362.","DOI":"10.1186\/s12882-019-1556-y"},{"issue":"11","key":"9613_CR33","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.2215\/CJN.02610319","volume":"14","author":"C Ginsberg","year":"2019","unstructured":"Ginsberg C, Houben A, Malhotra R, Berendschot T, Dagnelie PC, Kooman JP, et al. Serum phosphate and microvascular function in a population-based cohort. Clin J Am Soc Nephrol. 2019;14(11):1626\u201333.","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-020-09613-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-020-09613-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-020-09613-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T03:00:27Z","timestamp":1619751627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-020-09613-1"}},"subtitle":["Renal disease in chronic hypoparathyroidism"],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["9613"],"URL":"https:\/\/doi.org\/10.1007\/s11154-020-09613-1","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,18]]},"assertion":[{"value":"3 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"E. Gosmanova has served as a consultant for Shire, a Takeda company; P. Houillier has served as an advisory board member, speaker, and research investigator for Shire, a Takeda company; C. Marelli is an employee of Takeda Pharmaceuticals International AG, Zurich, Switzerland; L. Rejnmark has served as a consultant and speaker for Shire, a Takeda company; J. Bilezikian has served as an advisory committee\/board member, received consulting fees and grant\/research support, and acted as speaker for Shire, a Takeda company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}